- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00406809
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 2
- Faza 1
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Edmonton, Kanada, T6G 1Z2
- Site Reference ID/Investigator# 8941
-
-
-
-
California
-
Los Angeles, California, Stany Zjednoczone, 90033
- Site Reference ID/Investigator# 4997
-
Los Angeles, California, Stany Zjednoczone, 90095
- Site Reference ID/Investigator# 9104
-
-
Maryland
-
Bethesda, Maryland, Stany Zjednoczone, 20892
- Site Reference ID/Investigator# 2613
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone, 02215
- Site Reference ID/Investigator# 40243
-
Boston, Massachusetts, Stany Zjednoczone, 02215
- Site Reference ID/Investigator# 4745
-
-
New York
-
Buffalo, New York, Stany Zjednoczone, 14263
- Site Reference ID/Investigator# 2628
-
New York, New York, Stany Zjednoczone, 10016
- Site Reference ID/Investigator# 23543
-
New York, New York, Stany Zjednoczone, 10021
- Site Reference ID/Investigator# 2627
-
New York, New York, Stany Zjednoczone, 10032
- Site Reference ID/Investigator# 2614
-
New York, New York, Stany Zjednoczone, 10065
- Site Reference ID/Investigator# 5383
-
Rochester, New York, Stany Zjednoczone, 14642
- Site Reference ID/Investigator# 12306
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
Diagnoses:
- 1a/1b - lymphoid malignancy;
- 2a, Arm A - follicular lymphoma;
- 2a, Arm B - mantle cell, peripheral or cutaneous T-cell lymphomas including mycosis fungoides and Sezary syndrome or other indolent B-cell lymphomas such as marginal zone lymphoma;
- Received at least 1 prior chemotherapy treatment regimen (P1a/1b) and relapsed or refractory disease (P2a).
- Eastern Cooperative Oncology Group (ECOG) score of <= 1.
- Magnetic Resonance Imaging (MRI)/computed tomography (CT) negative for subdural or epidural hematoma w/in 28 days prior to first dose, if clinically indicated.
- Stable dose of Selective serotonin reuptake inhibitors (SSRI) antidepressants for at least 21 days prior to 1st dose.
Adequate bone marrow (BM) independent of any growth factor support (except with heavily infiltrated bone marrow (80% or more)):
- Absolute Neutrophil Count (ANC) >= 1000/µL;
- Platelets >= 100,000/mm3 (entry count must be independent of transfusion with in 14 days of Screening);
- Hemoglobin >= 9.0/dL.
Adequate coagulation, renal, and hepatic function:
- Serum creatinine <= 2.0 mg/dL or calculated creatinine clearance >= 50 mL/min;
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 3.0 x Upper Limit of Normal (ULN);
- Bilirubin <= 1.5 x ULN;
- Gilbert's Syndrome may have a bilirubin > 1.5 x ULN;
- Coagulation: Activated partial thromboplastin time (aPTT), Prothrombin Time (PT), not to exceed 1.2 x ULN
- Females must be surgically sterile, postmenopausal (at least 1 year), or negative results for a pregnancy test performed at Screening on a serum sample obtained with in 14 days prior to initial dose, and prior to dosing on a urine sample obtained on C1 D-3 (P1a) or Lead-in D1 (P1b, P2a) if > 7 days since serum results.
- Females not surgically sterile or postmenopausal (at least 1 year) and non-vasectomized males must practice birth control.
P2a only: History of autologous stem cell transplant must be > 6 months post transplant with adequate BM independent of growth factor support per lab reference range at Screening as follows:
- Absolute Neutrophil Count (ANC) >= 1,500/µL;
- Platelets >= 125,000/mm3 (entry platelet count must be independent of transfusion with in 14 days of Screening);
- Hemoglobin >= 10.0g/dL;
- Measurable disease by International Working Group (IWG)/National Cancer Institute- sponsored Working Group (NCI-WG) criteria.
At least one of following for Pharmacodynamics (P2a):
- archived diagnostic Formalin Fixed Paraffin Embedded (FFPE) tumor tissue with no intervening treatment since biopsy,
- core needle biopsy of malignant lymph node, or
- bone marrow aspirate or core positive for lymphoma.
Extension Study Inclusion Criteria Phase 2a subjects who enter the Extension Study must continue to meet all Inclusion and Exclusion criteria, with the exception of Inclusion Criterion regarding measurable disease by International Working Group (IWG)/National Cancer Institute- sponsored Working Group (NCI-WG) criteria and Inclusion Criteria regarding laboratory parameters for hematology, coagulation, and chemistry. Subjects entering the Extension Study must also have stable lab values per applicable laboratory reference ranges. In addition, subjects must also meet the following criteria:
Subjects must meet the following hematology and coagulation lab criteria:
- Platelet counts must be >= 25,000/mm3 (untransfused). Platelet counts <= 50,000/mm3 must be stable and monitored at an increased frequency at the discretion of the investigator.
- Absolute Neutrophil count (ANC) >= 500/µL. ANC >= 500/µL and < 1,000/µL should be monitored at an increased frequency at the discretion of the investigator.
- Hemoglobin of >= 8.0 g/dL.
- aPTT, PT is not to exceed 1.2 x ULN.
Chemistry values must not exceed Grade 2. Grade 2 chemistry labs should be monitored at an increased frequency at the discretion of the investigator. Subjects must meet the following chemistry criteria:
- Serum creatinine <= 3.0 x the upper normal limit (ULN) of institution's normal range. * AST and ALT <= 5.0 x the upper normal limit (ULN) of institution's normal range.
- Bilirubin <= 3.0 x ULN. Subjects with Gilbert's Syndrome may be allowed to have a Bilirubin > 3.0 x ULN based on a joint decision between the investigator and Abbott medical monitor.
Exclusion Criteria:
- History of, or is, clinically suspicious for cancer-related Central Nervous System (CNS) disease, lymphoid or non-lymphoid.
- Undergone an allogeneic or autologous stem cell transplant.
- Underlying, predisposing condition of bleeding or currently exhibits signs of clinically significant bleeding.
- Recent history of non-chemotherapy induced thrombocytopenic associated bleeding with in 1 year prior to first dose.
- Active peptic ulcer disease or other hemorrhagic esophagitis/gastritis.
- Active immune thrombocytopenic purpura or history of being refractory to platelet transfusions with in 1 year prior to first dose.
- Significant history of cardiovascular disease, renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, or hepatic disease.
- Females pregnant or breast-feeding.
- Positive for human immunodeficiency virus (HIV)
- History of other active malignancies with in the past 3 years (P1a/1b) or past 5 years (P2a), except adequately treated in situ carcinoma of the cervix uteri; basal or squamous cell carcinoma; in situ carcinoma of the bladder; previous malignancy confined and surgically resected with curative intent.
- Evidence of other clinically significant uncontrolled condition(s), including, but not limited to active systemic fungal infection; diagnosis of fever and neutropenia with in 1 week prior to study drug.
- Received steroid therapy with in 7 days prior to 1st dose of study drug for anti-neoplastic intent.
- Received any anti-cancer therapy, including chemotherapy, immunotherapy, radiotherapy, hormonal or any investigational therapy, with in 14 days prior to first dose of study drug, or has not recovered to <Gr2 clinically significant AE(s) /toxicity(s) of the previous therapy.
- Received a biologic with in 30 days prior to first dose.
- Currently receiving or requires anticoagulation therapy or any drugs or herbal supplements that affect platelet function, with the exception of low-dose anticoagulation medications that are used to maintain the patency of a central venous catheter.
- Received aspirin with in 7 days prior to first dose and during ABT-263 administration.
- Consumed grapefruit or grapefruit products with in 3 days prior to first dose.
- P1a/1b only: Diagnosed with Posttransplant lymphoproliferative disorder (PTLD); Burkitt's, Burkitt-like, or HIV-associate lymphoma; lymphoblastic lymphoma/leukemia; or multiple myeloma.
- Subject has received CYP3A inhibitors (e.g., ketoconazole, clarithromycin) within 7 days prior to the administration of the first dose of ABT-263 (P2a).
- Subject had a prior significant toxicity from another Bcl-2 family protein inhibitor (P2a).
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nielosowe
- Model interwencyjny: Zadanie sekwencyjne
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: Phase 1a and 1b
Relapsed or refractory lymphoid malignancies
|
Oral solution Phase 1 dosing was under two different schedules: 14 days on drug, 7 days off or 21 days continuous dosing. Oral solution and tablets Phase 2a dosing under 21 day continuous dosing. - 150 mg lead-in dose for 7-14 days followed by a 325 mg continuous once daily dose. |
Eksperymentalny: Arm A (Phase 2a)
Relapsed or refractory follicular lymphoma
|
Oral solution Phase 1 dosing was under two different schedules: 14 days on drug, 7 days off or 21 days continuous dosing. Oral solution and tablets Phase 2a dosing under 21 day continuous dosing. - 150 mg lead-in dose for 7-14 days followed by a 325 mg continuous once daily dose. |
Eksperymentalny: Arm B (Phase 2a)
Relapsed or refractory mantle cell, peripheral T-cell, cutaneous T-cell lymphoma including mycosis fungoides and Sezary syndrome, or other indolent B-cell lymphomas such as marginal zone lymphoma
|
Oral solution Phase 1 dosing was under two different schedules: 14 days on drug, 7 days off or 21 days continuous dosing. Oral solution and tablets Phase 2a dosing under 21 day continuous dosing. - 150 mg lead-in dose for 7-14 days followed by a 325 mg continuous once daily dose. |
Eksperymentalny: Extension Study
Relapsed or refractory follicular lymphoma or Relapsed or refractory mantle cell, peripheral T-cell, cutaneous T-cell lymphoma including mycosis fungoides and Sezary syndrome, or other indolent B-cell lymphomas such as marginal zone lymphoma
|
Oral solution Phase 1 dosing was under two different schedules: 14 days on drug, 7 days off or 21 days continuous dosing. Oral solution and tablets Phase 2a dosing under 21 day continuous dosing. - 150 mg lead-in dose for 7-14 days followed by a 325 mg continuous once daily dose. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Phase 1a: Determine dose limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended Phase 2 dose (RPTD) and schedule - intermittent dosing.
Ramy czasowe: Repeating sequence of 14 days on therapy and 7 days off.
|
1a: Determination of dose limiting toxicity (DLT) and maximum tolerated dose (MTD) under a 14/21 day dosing schedule
|
Repeating sequence of 14 days on therapy and 7 days off.
|
Phase 1b: Determine dose limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended Phase 2 dose (RPTD) and schedule - continuous dosing.
Ramy czasowe: 21 day continuous dosing.
|
Phase 1b: Determination of ABT-263 dose limiting toxicity (DLT) and maximum tolerated dose (MTD) under a 21 day continuous dosing schedule.
|
21 day continuous dosing.
|
Phase 2a: Continued assessment of safety profile at the recommended Phase 2 dose (RPTD) and schedule - continuous dosing.
Ramy czasowe: 21 day continuous dosing.
|
Phase 2a: Continued assessment of the safety profile of ABT-263 at the Recommended Phase 2 Dose (RPTD) and schedule under a 21 day continuous dosing.
|
21 day continuous dosing.
|
Phase 2a: Assessment of preliminary efficacy signals including biomarker assessment - continuous dosing.
Ramy czasowe: 21 day continuous dosing.
|
Phase 2a: Assessment of the preliminary efficacy signals of ABT-263, including biomarker assessment, at the Recommended Phase 2 Dose (RPTD) and schedule under a 21 day continuous dosing.
|
21 day continuous dosing.
|
Extension Study: Continued assessment of the safety profile of ABT-263
Ramy czasowe: 21 day continuous dosing
|
Continued assessment of the safety profile of ABT-263.
|
21 day continuous dosing
|
Extension Study: Continued assessment of the preliminary efficacy signals of ABT-263.
Ramy czasowe: day continuous dosing
|
Continued assessment of the preliminary efficacy signals of ABT-263.
|
day continuous dosing
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Phase 1a or Phase 1b safety assessment
Ramy czasowe: Repeating sequence of 14 days on therapy and 7 days off OR 21 day continuous dosing.
|
Assessment of the safety of ABT-263
|
Repeating sequence of 14 days on therapy and 7 days off OR 21 day continuous dosing.
|
Phase 1a, Phase 1b, or Phase 2a pharmacokinetic profile evaluation
Ramy czasowe: Repeating sequence of 14 days on therapy and 7 days off OR 21 day continuous dosing.
|
Evaluation of pharmacokinetic profile of ABT-263.
|
Repeating sequence of 14 days on therapy and 7 days off OR 21 day continuous dosing.
|
Phase 1a effect of food on bioavailability
Ramy czasowe: Repeating sequence of 14 days on therapy and 7 days off.
|
Evaluation of the effect of food on bioavailability
|
Repeating sequence of 14 days on therapy and 7 days off.
|
Współpracownicy i badacze
Sponsor
Śledczy
- Dyrektor Studium: Mack Mabry, MD, AbbVie
Publikacje i pomocne linki
Publikacje ogólne
- Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, Tulpule A, Dunleavy K, Xiong H, Chiu YL, Cui Y, Busman T, Elmore SW, Rosenberg SH, Krivoshik AP, Enschede SH, Humerickhouse RA. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010 Dec;11(12):1149-59. doi: 10.1016/S1470-2045(10)70261-8. Epub 2010 Nov 18.
- de Vos S, Leonard JP, Friedberg JW, Zain J, Dunleavy K, Humerickhouse R, Hayslip J, Pesko J, Wilson WH. Safety and efficacy of navitoclax, a BCL-2 and BCL-XL inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study. Leuk Lymphoma. 2021 Apr;62(4):810-818. doi: 10.1080/10428194.2020.1845332. Epub 2020 Nov 25.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby układu odpornościowego
- Nowotwory według typu histologicznego
- Zaburzenia limfoproliferacyjne
- Choroby limfatyczne
- Zaburzenia immunoproliferacyjne
- Białaczka
- Białaczka, komórki B
- Nowotwory
- Chłoniak
- Chłoniak, Pęcherzykowy
- Chłoniak nieziarniczy
- Chłoniak, Komórki Płaszcza
- Białaczka, Limfocytowa, Przewlekła, B-Cell
- Białaczka, układ limfatyczny
- Chłoniak, T-komórkowy
- Chłoniak z komórek T, obwodowy
- Środki przeciwnowotworowe
- Nawitoklaks
Inne numery identyfikacyjne badania
- M06-814
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Chłoniak grudkowy
-
Yale UniversityWycofaneRak układu krwiotwórczego/chłonnego | Zakaźna mononukleoza | PTLD | Guz limfatyczny | Hiperplazja plazmocytowa PTLD | Florid Follicular Hyperplasia PTLD | Polimorficzny PTLD | Monomorficzny PTLD | Klasyczny chłoniak Hodgkina typu PTLDStany Zjednoczone
-
Gilead SciencesZakończonyChłoniak grudkowy | Chłoniak z komórek płaszcza | Przewlekła białaczka limfocytowa | Rozlany chłoniak z dużych komórek B | Non-FL Indolent Non-Hodgkin's LymphomaStany Zjednoczone, Kanada
Badania kliniczne na ABT-263
-
Kathleen LudwigDo dyspozycjiDzieciństwo nawracające WSZYSTKO | Nawracający chłoniak limfoblastyczny wieku dziecięcegoStany Zjednoczone
-
AbbVieDo dyspozycjiZwłóknienie szpiku | Chłoniak limfoblastyczny | Ostra białaczka limfocytowa (ALL)Stany Zjednoczone
-
AbbVie (prior sponsor, Abbott)ZakończonyPrzewlekła białaczka limfocytowaStany Zjednoczone, Australia, Izrael, Polska, Ukraina
-
AbbottGenentech, Inc.ZakończonyZdrowe kobietyStany Zjednoczone
-
AbbVieAktywny, nie rekrutującyZwłóknienie szpiku (MF)Stany Zjednoczone, Australia, Austria, Belgia, Bułgaria, Kanada, Chorwacja, Francja, Niemcy, Grecja, Izrael, Włochy, Japonia, Republika Korei, Holandia, Nowa Zelandia, Federacja Rosyjska, Serbia, Afryka Południowa, Hiszpania, Sz... i więcej
-
AbbVieAktywny, nie rekrutującyZwłóknienie szpiku (MF)Stany Zjednoczone, Argentyna, Australia, Brazylia, Bułgaria, Chile, Węgry, Izrael, Włochy, Japonia, Republika Korei, Hiszpania, Szwecja, Indyk
-
AbbVieZakończonyZwłóknienie szpiku (MF)Stany Zjednoczone, Republika Korei, Afryka Południowa
-
National Cancer Institute (NCI)ZakończonyOporny na leczenie złośliwy nowotwór lity | Nawracający złośliwy nowotwór lity | Przerzutowy złośliwy nowotwór lity | Nieoperacyjny lity nowotwór | Nawracający rak drobnokomórkowy płuca | Stopień IIIA Rak drobnokomórkowy płuca AJCC v7 | Etap IIIB Rak drobnokomórkowy płuca AJCC v7 | Rak drobnokomórkowy... i inne warunkiStany Zjednoczone
-
City of Hope Medical CenterNational Cancer Institute (NCI)RekrutacyjnyNawracająca ostra białaczka szpikowa | Oporna na leczenie ostra białaczka szpikowaStany Zjednoczone
-
AbbVieGenentech, Inc.ZakończonyPrzewlekła białaczka limfocytowaStany Zjednoczone, Australia, Niemcy, Zjednoczone Królestwo